BAMF Health
- Company typePrivate
- Founded2016
- HeadquartersGrand Rapids, United States
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
BAMF Health firmographics
Firmographics- Name
- BAMF Health
- Legal name
- BAMF Health, Inc.
- Website
- https://bamfhealth.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Where BAMF Health is headquartered
LocationHeadquarters
- HQ city
- Grand Rapids
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
BAMF Health business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Patient Treatment Services: BAMF Health generates revenue through providing molecular imaging and radiopharmaceutical therapy services directly to patients for cancer treatment (prostate cancer, neuroendocrine tumors, breast cancer, etc.) and Alzheimer's disease
- Clinical Trial Services: BAMF RadioNexus provides clinical trial enablement services to pharmaceutical sponsors, including trial setup, execution, patient enrollment, and regulatory support for radiopharmaceutical studies
- CDMO Radiopharmacy Services: Contract development and manufacturing organization providing radiopharmaceutical production services for pharmaceutical companies, including clinical trial manufacturing and commercial production
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Treatment services - Contact for pricing |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels8 records
BAMF Health product offering
Product offeringCore offering
BAMF Health operates a vertically integrated theranostics center that combines molecular imaging (PET/CT, PET/MR, SPECT/CT) with radiopharmaceutical therapy and an in-house dual-cyclotron radiopharmacy to diagnose and treat cancers (prostate, neuroendocrine, breast, lung) and Alzheimer's disease. The company also runs the BAMF RadioNexus clinical trials network for radiopharmaceutical research and provides CDMO contract radiopharmaceutical manufacturing services to pharmaceutical sponsors.
Differentiator
Problem solved
Functional benefit
Brands
- RadioNexus: First-of-its-kind clinical trials network dedicated exclusively to radiopharmaceutical research, partnering with pharmaceutical sponsors and health systems.
- FMAB (Foundation for Medical Advancement and Breakthroughs)
Quantifiable outcome
- Total-body PET scan in less than 5 minutes compared to 40 minutes with conventional scanners
- +3 more outcomes
Companies that use BAMF Health
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
BAMF Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
BAMF Health partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and major.
- Sentara HealthcoreJoint venture to create Virginia's first vertically integrated comprehensive Theranostics program. Sentara is one of the largest health systems in the Mid-Atlantic and Southeast with 35,000 employees and 12 hospitals.
- The University of Kansas Health SystemcorePartnership to develop fully integrated theranostics platform for both adult and pediatric patients. Combines diagnostic imaging and targeted therapy expanding access and fostering research in precision medicine.
- University of Kansas Medical CentercorePartnership to develop integrated theranostics platform. Collaborative effort bringing together academic medical center expertise and BAMF's theranostics capabilities.
- Children's MercycorePartnership to develop integrated theranostics platform for pediatric patients. Specialized pediatric healthcare expertise combined with BAMF's precision medicine capabilities.
- Henry Ford HealthcoreJoint venture to establish Comprehensive Theranostics Center in downtown Detroit. 45,000-square-foot facility within Bedrock's Gratiot Life Sciences Building. Combines BAMF's global leadership in Theranostics with Henry Ford's century-long legacy of clinical excellence.
- East River Medical ImagingmajorFirst BAMF RadioNexus site in the New York City area. Partnership brings new cancer trials and treatments to patients in New York City and Westchester.
- Calyx / InvicromajorStrategic collaboration to accelerate clinical translation of radioligand therapies and immuno-oncology agents. Enhances and speeds up therapy development process.
- Corewell HealthmajorClinical trial partnership to investigate new targeted liquid radiation therapy for cancer patients whose chemotherapy treatments have been unsuccessful.
- GE HealthCarecoreStrategic partnership to enable sustainable and scalable solutions for growth in Theranostics. Includes training collaboration for GE engineers at BAMF facility.
- SOFIE BiosciencesmajorPartnership to accelerate time to clinical trial launch for pancreatic cancer detection technology.
- ITM Isotope Technologies Munich SEmajorGlobal cooperation agreement for targeted radiopharmaceuticals in U.S. radiopharmacy and clinic network. Enables access to ITM's radiopharmaceutical products and expertise.
- Telix PharmaceuticalsmajorPartnership using Illuccix (Ga-68 gozetotide injection) for first total-body PET scans with uEXPLORER for prostate cancer imaging.
- United ImagingcoreGlobal strategic partnership advancing theranostics and precision medicine. BAMF purchased first uEXPLORER total-body scanner and uPMR 790 PET/MR for clinical use in the United States.
Scale indicators6 records
Recent moves10 records
Expansion highlights6 records
BAMF Health competitors and assessment
Company assessmentDirect peers
- Lantheus Holdings: Major US radiopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals for oncology, including PYLARIFY for PSMA PET imaging. Both BAMF Health and Lantheus produce and supply radiopharmaceuticals for cancer imaging and therapy, with BAMF's CDMO radiopharmacy operating in direct competition with Lantheus's commercial supply network.
- Telix Pharmaceuticals: Australia-based radiopharmaceutical company with a strong US presence, developing diagnostic and therapeutic agents including Illuccix (Ga-68 gozetotide), which BAMF uses for uEXPLORER total-body PET prostate cancer imaging. Telix is both a BAMF technology partner and a competitor in the broader radiopharmaceutical development and commercialization market.
- ITM Isotope Technologies Munich: Germany-based radiopharmaceutical company producing targeted radionuclide therapies for cancer. BAMF Health signed a global cooperation agreement with ITM to access its radiopharmaceutical products for the US radiopharmacy and clinic network, positioning ITM as both a partner and a competitor in radiopharmaceutical supply.
- Curium Pharma: One of the world's largest radiopharmaceutical companies, manufacturing and distributing diagnostic and therapeutic radiopharmaceuticals globally with deep expertise in nuclear medicine. Both BAMF Health and Curium operate radiopharmacy production networks supplying imaging agents and therapeutic isotopes to clinical sites, making Curium a directly comparable supplier.
- SOFIE Biosciences: Radiopharmaceutical company developing diagnostic and therapeutic agents with focus on pancreatic cancer detection and other solid tumors. BAMF Health partnered with SOFIE to accelerate pancreatic cancer detection technology through clinical trials, positioning SOFIE as both a development partner and a future supplier of novel radiopharmaceuticals.
- Excel Diagnostics & Nuclear Oncology Center: One of the largest private theranostics centers in the US, providing molecular imaging and radiopharmaceutical therapy services to cancer patients from a single specialty clinic footprint. Excel Diagnostics is the most directly comparable specialty theranostics clinic to BAMF Health in terms of clinical service delivery model and patient population served.
Broad incumbents
- Novartis: Global pharmaceutical company that owns the dominant radiopharmaceutical franchises Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), which BAMF Health administers to its prostate cancer and neuroendocrine tumor patients. Novartis is the upstream therapeutic supplier whose products fuel much of BAMF's clinical service volume.
- GE HealthCare: Global medical technology and diagnostics company providing imaging equipment and theranostics solutions. BAMF Health has a strategic partnership with GE HealthCare for training and technology advancement and is the first U.S. clinic to receive the GE Starguide SPECT/CT scanner, positioning GE as both a flagship partner and a broader imaging incumbent.
- Siemens Healthineers: Global medical technology company with a major PETNET Solutions radiopharmacy network across the US, providing centralized radiopharmaceutical production and distribution. Siemens competes with BAMF Health's CDMO radiopharmacy services through PETNET while also supplying PET/CT and PET/MR imaging equipment used in clinical theranostics workflows.
- Bayer: Global pharmaceutical company with a radiopharmaceutical franchise including Xofigo (radium-223 dichloride) for metastatic castration-resistant prostate cancer — a therapy class directly relevant to BAMF's patient population. Bayer represents a broader pharmaceutical incumbent with deep radiopharma commercial capability that competes in the same therapy indications BAMF treats.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BAMF Health social profiles
Digital presenceBAMF Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
BAMF Health leadership team
Management profileNumber of profiles
Profiles11 records
BAMF Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
BAMF Health funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BAMF Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BAMF Health
What does BAMF Health do?
BAMF Health operates a vertically integrated theranostics center that combines molecular imaging (PET/CT, PET/MR, SPECT/CT) with radiopharmaceutical therapy and an in-house dual-cyclotron radiopharmacy to diagnose and treat cancers (prostate, neuroendocrine, breast, lung) and Alzheimer's disease. The company also runs the BAMF RadioNexus clinical trials network for radiopharmaceutical research and provides CDMO contract radiopharmaceutical manufacturing services to pharmaceutical sponsors.
Is BAMF Health a public or private company?
BAMF Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was BAMF Health founded?
BAMF Health was founded in 2016. It employs 101 to 250 people.
Where is BAMF Health based?
BAMF Health is headquartered in Grand Rapids, United States, in the North America region.
How does BAMF Health make money?
Three revenue lines are on record. Patient Treatment Services are the primary driver. The others are clinical Trial Services and CDMO Radiopharmacy Services.
Who are BAMF Health's main competitors?
Direct peers on record are Lantheus Holdings, Telix Pharmaceuticals, ITM Isotope Technologies Munich, Curium Pharma, SOFIE Biosciences and Excel Diagnostics & Nuclear Oncology Center. Broad incumbents are Novartis, GE HealthCare, Siemens Healthineers and Bayer.
Does BAMF Health have an API?
No public API is recorded for BAMF Health.